NCT04858607 (CoVVac) is a clinical trial of Blood sample in Covid19, sponsored by Medical University of Graz.

Who is sponsoring NCT04858607?

NCT04858607 is sponsored by Medical University of Graz.

What drugs are being tested in NCT04858607?

Interventions in NCT04858607: Blood sample, Saliva sample.

What condition does NCT04858607 study?

NCT04858607 studies Covid19, Immunosuppression.

Is NCT04858607 still recruiting?

NCT04858607 is currently completed. Last updated 9 February 2023.

Last reviewed 2023-02-09 · How we verify

NCT04858607: CoVVac

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Humoral and Cellular Immune Response to COVID-19 Vaccines in Immunocompromised and Healthy Individuals

Completed Last updated 9 February 2023

What this trial tests

trial testing Blood sample in Covid19 in 373 participants. Completed in 20 January 2023.

Timeline

19 April 2021

Primary endpoint
20 January 2023

20 January 2023

Quick facts

Lead sponsor	Medical University of Graz
Status	Completed
Study type	OBSERVATIONAL
Enrollment	373
Start date	19 April 2021
Primary completion	20 January 2023
Estimated completion	20 January 2023
Sites	1 location across Austria

Drugs / interventions tested

Blood sample — full drug profile →
Saliva sample — full drug profile →

Conditions studied

Covid19 — all drugs for Covid19 →
Immunosuppression — all drugs for Immunosuppression →

Sponsor

Medical University of Graz

Who can join

16 and older, any sex, with Covid19 or Immunosuppression. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Currently, the efficacy of COVID-19 vaccination in immunodeficient patients is unknown. Here the investigators aim to evaluate the efficacy of COVID-19 vaccines in immunodeficient patients compared to healthy controls. The investigators will assess the humoral and cellular response to COVID-19 vaccination in these subjects in detail. Furthermore, factors associated with good response to vaccination will be identified. The results of this study will help to guide future recommendations on COVID-19 vaccination in this population.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

CD19+IgD+CD27- Naïve B Cells as Predictors of Humoral Response to COVID 19 mRNA Vaccination in Immunocompromised Patients.
Schulz E, Hodl I, Forstner P, Hatzl S, et al · · 2021 · cited 34× · PMID 34950155 · DOI 10.3389/fimmu.2021.803742
Phase 4 clinical trials in the era of the Coronavirus Disease (COVID-19) pandemic and their importance to optimize the COVID-19 vaccination.
Ralise AEG, Camargo TM, Marson FAL. · · 2023 · cited 8× · PMID 37449956 · DOI 10.1080/21645515.2023.2234784
Altered cellular immune response to vaccination against SARS-CoV-2 in patients suffering from autoimmunity with B-cell depleting therapy.
Hodl I, Sallegger C, Forstner P, Sareban N, et al · · 2023 · cited 4× · PMID 36681177 · DOI 10.1016/j.micinf.2023.105103
Jahrestagung der Österreichischen Gesellschaft für Rheumatologie & Rehabilitation : 25.–27. November 2021
· 2021
CD19+IgD+CD27- naïve B Cells as predictors of humoral response to COVID-19 mRNA vaccination in immunocompromised patients
Schulz E, Hodl I, Forstner P, Hatzl S, et al · · 2021 · DOI 10.1101/2021.08.11.21261898

Verify or expand the search:

Other trials of Blood sample

Trials testing the same drug.

NCT07226466 — Evaluating Biomarkers of Cognitive Dysfunction in Patients With Cancer · not yet recruiting
NCT07313878 — Evaluation of Acute and Chronic Nephrotoxicity in Acute Lymphatic Leukemia Patients Using Ultrasound Localization Micros · NA · recruiting
NCT06273800 — Chemosensitivity During Phases of the Menstrual Cycle in Breast Cancer Patients · NA · recruiting
NCT07030205 — Resting-state Imaging and OSteoporosiS · NA · recruiting
NCT07295808 — Identification and Characterisation of IgA With Nephritogenic Potential in IgA Deposition Nephropathies (Rep-IgAN) · NA · recruiting

Other recruiting trials for Covid19

Currently open trials in the same condition.

NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting

Other Medical University of Graz trials

Trials by the same sponsor.

NCT07498244 — Collagen Fingerprinting for Stratification of Pulmonary Hypertension (PH) Patients · recruiting
NCT07492823 — Clinical Applicability of Liquid Biopsy in Chondrosarcoma · not yet recruiting
NCT07297615 — 3D Liver Volumetry · NA · not yet recruiting
NCT07588282 — The Effect of Psychoeducational Diagnosis Communication on Perception of Illness, Satisfaction, and Behavioral Intention · NA · recruiting
NCT07376096 — Liquid Biopsy in Germ Cell Tumors · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04858607 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medical University of Graz
Last refreshed: 9 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04858607.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing